Group 1 - The company received a notification regarding the progress of the Phase II clinical trial for the innovative drug UB-221, which has completed the enrollment of all 145 participants [1] - The clinical trial is a Phase II, multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria (CSU) [1] - The trial planned to recruit 144 patients but ultimately enrolled 145, with participants randomly assigned to one of five treatment groups [1] Group 2 - The company is focused on building a world-class high-tech biopharmaceutical company, leveraging its diverse biopharmaceutical technology platform and talent pool to expand its business boundaries [2] - The company is actively developing three innovative drugs: UB-221, UB-421, and UB-621, while also exploring new indications for these drugs [2] - The company aims to transition from animal health to human pharmaceuticals by utilizing its technological expertise in synthetic peptides, genetic engineering, and mRNA, alongside its capabilities in innovative drug development management [2]